Home / Deep Research / Schwannoma

Schwannoma

1. Disease Information

2026-06-08
Falcon MONDO:0002546 Model: Edison Scientific Literature 29 citations

1. Disease Information

1.1 Definition and overview

1.2 Key identifiers and ontology mappings (available in current corpus)

  • MONDO
  • Schwannomatosis: MONDO_0008075 (OpenTargets mapping) (OpenTargets Search: schwannoma,vestibular schwannoma,schwannomatosis)
  • NF2-related schwannomatosis: MONDO_0007039 (OpenTargets mapping) (OpenTargets Search: schwannoma,vestibular schwannoma,schwannomatosis)
  • EFO
  • Schwannoma: EFO_0000693 (OpenTargets mapping) (OpenTargets Search: schwannoma,vestibular schwannoma,schwannomatosis)

Not retrieved in the current evidence set (therefore not asserted here): MeSH ID, ICD-10/ICD-11 codes, Orphanet/OMIM identifiers for schwannoma/VS.

1.3 Common synonyms / alternative names

1.4 Evidence-source type

The consensus terminology/diagnostic criteria and clinical outcomes summarized below are derived from aggregated disease-level resources (systematic reviews, consensus updates, surveillance recommendations) plus clinical cohort studies and ClinicalTrials.gov registrations (chiranth2023asystematicreview pages 1-2, screnci2024bevacizumabforvestibular pages 1-2, douwes2024bevacizumabtreatmentfor pages 9-11, NCT04374305 chunk 1).

2. Etiology

2.1 Primary causal factors

2.1.1 Sporadic schwannoma / VS

2.1.2 Schwannomatosis syndromes (germline predisposition)

A key 2022–2025 development is gene-based classification of “schwannomatoses” as cancer predisposition syndromes caused by germline pathogenic variants: * Perrino et al. (2025) abstract: “Schwannomatoses (SWN) are distinct cancer predisposition syndromes caused by germline pathogenic variants in the genes NF2, SMARCB1, or LZTR1.” (Feb 2025) (perrino2025updateoncancer pages 3-4) * Perrino et al. (2025) abstract: “Neurofibromatosis type 2 was recently renamed as NF2-related SWN …” (perrino2025updateoncancer pages 3-4)

OpenTargets also highlights NF2, SMARCB1, and LZTR1 as top disease-associated targets for schwannoma/schwannomatosis, consistent with genetic causality in these syndromes (OpenTargets Search: schwannoma,vestibular schwannoma,schwannomatosis).

2.2 Risk factors

Environmental/lifestyle risk factors: not established in the retrieved evidence for schwannoma causation. A 2023 review on hearing loss and VS notes attention to “environmental factors” that could contribute to hearing loss progression, but does not provide validated causal environmental risk factors for schwannoma itself in the retrieved excerpt (otaner2026vestibularschwannomagenetic pages 1-2).

2.3 Protective factors / gene–environment interactions

Not identified in the retrieved evidence set.

3. Phenotypes (clinical features)

3.1 Core phenotype spectrum (with suggested HPO terms)

Vestibular schwannoma (sporadic or NF2-related)

Schwannomatosis syndromes (NF2-, SMARCB1-, LZTR1-related)

3.2 Age of onset / progression

3.3 Quality-of-life impact

4. Genetic/Molecular Information

4.1 Causal genes and molecular classification (2022 consensus framework)

2022 consensus updates changed both nomenclature and diagnostic criteria: * “Schwannomatosis” used as an umbrella term for disorders that predispose to schwannomas, and each type is classified by the causative gene; “NF2 is now termed NF2-related schwannomatosis.” (Tamura 2024) (tamura2024historicaldevelopmentof pages 1-3) * Gene-based syndromes highlighted in 2025 surveillance perspective: NF2-, SMARCB1-, LZTR1-related schwannomatosis (perrino2025updateoncancer pages 3-4).

4.2 Pathogenic variants / variant origin

4.3 Pathways and mechanisms (current understanding; 2023–2024 emphasis)

  • Review synthesis for VS: merlin deficiency leads to dysregulation of Hippo/YAP-TAZ, PI3K/AKT/mTOR, VEGF, MAPK, and adhesion pathways (otaner2026vestibularschwannomagenetic pages 1-2).
  • Mechanistic review of NF2 (2024, NPJ Precision Oncology): merlin is an ERM-family scaffold; NF2 loss dysregulates Hippo kinase cascades converging on LATS1/2, enabling YAP-driven transcription; therapeutic concepts include targeting Hippo/YAP, mTOR, FAK, and others (xu2024nf2anunderestimated pages 2-3).

4.3.1 Hippo–YAP/TAZ–TEAD as a therapeutic vulnerability (primary evidence)

A key 2023 advance is direct preclinical demonstration that inhibiting TEAD activity can regress schwannoma: * Laraba et al. (Brain, Sep 2023) used human primary schwannoma cells and mouse schwannoma models and found that genetic ablation of YAP/TAZ or TEAD palmitoylation inhibitors can block and regress schwannoma growth, supporting Hippo pathway targeting (laraba2023inhibitionofyaptazdriven pages 1-2, laraba2023inhibitionofyaptazdriven pages 2-3).

Visual evidence: the in vivo regression effect with TEAD auto-palmitoylation inhibitors is shown in a central figure with tumor-volume reductions and increased apoptosis (cropped figure region) (laraba2023inhibitionofyaptazdriven media d8f8c3e0).

4.4 Epigenetic / multi-omics profiling

Not retrievable here: specific methylation signatures, transcriptomic/proteomic markers, or single-cell datasets are referenced in some reviews but not captured with extractable quantitative details in the current evidence excerpts.

Suggested GO / CL terms (for knowledge-base annotation)

  • Key biological processes (GO):
  • Hippo signaling (e.g., GO:0035329 hippo signaling)
  • Regulation of cell proliferation (GO:0042127)
  • Angiogenesis / VEGF signaling (GO:0001525 angiogenesis)
  • Cell types (CL):
  • Schwann cell (CL:0000218)

5. Environmental Information

No validated causal environmental exposures for schwannoma were identified in the retrieved evidence set. Environmental factors are discussed in the context of hearing loss broadly, but without definitive etiologic linkage to schwannoma occurrence in the excerpts available (otaner2026vestibularschwannomagenetic pages 1-2).

6. Mechanism / Pathophysiology (causal chain)

6.1 Example causal chain: NF2 loss → pathway dysregulation → tumor growth and hearing loss

  1. Initial trigger: NF2 inactivation (germline + second hit in syndromic disease; somatic loss in sporadic VS). (otaner2026vestibularschwannomagenetic pages 1-2, tamura2024historicaldevelopmentof pages 3-4)
  2. Upstream molecular consequence: loss of merlin’s tumor-suppressive scaffolding and regulation of contact inhibition and Hippo kinase activation. (xu2024nf2anunderestimated pages 2-3)
  3. Downstream transcriptional programs: increased YAP/TAZ–TEAD activity; additional dysregulation in PI3K/AKT/mTOR, MAPK, VEGF pathways (review synthesis). (otaner2026vestibularschwannomagenetic pages 1-2)
  4. Cellular phenotype: Schwann-cell proliferation and tumor maintenance; vascular and inflammatory changes may contribute to hearing loss beyond pure nerve compression. (otaner2026vestibularschwannomagenetic pages 1-2)

6.2 Hearing loss mechanisms in VS

VS-associated hearing loss described as multifactorial, involving tumor-secreted factors, inflammation, vascular changes, and inner ear damage, alongside nerve compression (otaner2026vestibularschwannomagenetic pages 1-2).

7. Anatomical Structures Affected

7.1 Organ and system level (with UBERON suggestions)

7.2 Tissue/cell level

7.3 Subcellular level

Not specifically defined in retrieved evidence excerpts.

8. Temporal Development

9. Inheritance and Population

9.1 Inheritance

9.2 Epidemiology statistics (from retrieved sources)

Note: Incidence/prevalence for all schwannomas (sporadic) were not retrieved in the current evidence set.

10. Diagnostics

10.1 2022 international diagnostic criteria highlights (NF2-related schwannomatosis)

Tamura et al. (2024) summarizes consensus criteria: * Diagnosis can be made by (1) bilateral vestibular schwannomas, (2) an identical NF2 pathogenic variant in ≥2 anatomically distinct NF2-related tumors, or (3) combinations of major/minor criteria (tamura2024historicaldevelopmentof pages 3-4). * Mosaic NF2: “clearly less than 50%” pathogenic VAF in blood/saliva, or shared pathogenic variant across ≥2 anatomically unrelated tumors but absent from unaffected tissue (tamura2024historicaldevelopmentof pages 3-4).

10.2 Diagnostic testing modalities (from available evidence)

10.3 Differential diagnosis

Not systematically extractable from current excerpts (e.g., neurofibroma vs schwannoma, meningioma, MPNST). A 2025 review notes hybrid neurofibroma/schwannoma can be diagnostically confusing (retrieved but not evidence-extracted here).

11. Outcome / Prognosis

11.1 Treatment response metrics as prognostic indicators

Systemic therapy outcomes in NF2-related VS are commonly assessed using volumetric radiographic response (>20% decrease) and hearing response metrics (WRS, PTA), as used in systematic reviews and cohort studies (chiranth2023asystematicreview pages 1-2, douwes2024bevacizumabtreatmentfor pages 2-4).

11.2 Progression after stopping therapy

In a single-center cohort, post-treatment radiologic surveillance showed 55% progression after stopping bevacizumab (with median post-treatment follow-up 19.3 months), and symptom worsening was frequent after discontinuation (douwes2024bevacizumabtreatmentfor pages 8-9, douwes2024bevacizumabtreatmentfor pages 9-11).

12. Treatment (current applications and real-world implementations)

12.1 Standard local management

VS management options include observation, microsurgery, and stereotactic radiosurgery, as summarized in a recent narrative review (otaner2026vestibularschwannomagenetic pages 1-2).

12.2 Systemic therapies (NF2-related VS): bevacizumab and beyond

Bevacizumab (anti-VEGF monoclonal antibody) is consistently the systemic therapy with the strongest clinical signal in NF2-related VS, though generally off-label and supported mainly by single-arm/retrospective evidence (otaner2026vestibularschwannomagenetic pages 1-2, chiranth2023asystematicreview pages 1-2, douwes2024bevacizumabtreatmentfor pages 9-11).

The table below compiles key quantitative efficacy/toxicity statistics from 2023–2024 reviews and a 2024 real-world cohort.

Table (click to expand)
Source Population N Bevacizumab dose/schedule Radiographic response definition and rates Hearing response definition and rates Key adverse events and rates Notes
Chiranth et al., 2023, Neuro-Oncology Advances, DOI: https://doi.org/10.1093/noajnl/vdad099 NF2-related schwannomatosis with vestibular schwannoma; pooled systematic review of targeted therapy studies 200 across 10 bevacizumab studies (16 total studies tested 6 drugs) Review-level summary; notes that lower-dose bevacizumab may retain efficacy with less toxicity REiNS volumetric criteria: radiographic response (RR) = >20% tumor-volume decrease; progression = >20% increase. Pooled bevacizumab RR 38% (95% CI 31–45%); bevacizumab had highest efficacy among targeted agents reviewed Pooled hearing response (HR) 45% (95% CI 36–54%) Common toxicities: hypertension and menorrhagia Comparator agents in review: lapatinib RR 6%, HR 31%; VEGFR vaccine RR 29%, HR 40%. Authors conclude bevacizumab showed the highest efficacy, but further trials of other agents/combination therapy are needed (chiranth2023asystematicreview pages 1-2)
Screnci et al., 2024, Journal of Clinical Medicine, DOI: https://doi.org/10.3390/jcm13237488 Neurofibromatosis type 2 / NF2-related vestibular schwannoma; systematic review 176 across 9 studies Not consistently reported in pooled excerpt Partial tumor volume reduction defined as ≥20%: 40%; disease stabilization 50%; progression 10% Hearing improvement 36%; hearing stabilization 46%; hearing deterioration 18% Severe adverse effects in 13% (including hypertension and thromboembolic events); 18% reported no side effects Tumor regrowth observed in some patients after treatment discontinuation, supporting need for long-term monitoring (screnci2024bevacizumabforvestibular pages 1-2)
Douwes et al., 2024, Cancers, DOI: https://doi.org/10.3390/cancers16081479 Single-center NF2-related schwannomatosis cohort treated for target vestibular schwannoma 17 patients; radiology evaluable in 16; hearing evaluable in 15 target ears; post-treatment symptom surveillance in 11; post-treatment radiology in 12 Median 7.5 mg/kg IV every 3 weeks (range 5.6–7.5; interval range 3.0–4.4 weeks); planned regimen 7.5 mg/kg q3wk for at least 6 months; median duration 7.1 months (range 2.1–23.9) Definition: improved = ≥20% decrease in extrameatal volume; stable = between −20% and +20%; worsened = ≥20% increase. On treatment: regression 31% (5/16), stable 69% (11/16), no ≥20% progression reported. Median extrameatal volume 1.24 cm^3 to 1.15 cm^3. Pre-treatment growth 43% overall (15% annually) vs −12% overall (−13% annually) during treatment. Post-treatment surveillance: 9% regression, 36% stable, 55% progression Definition: improved = ≥10% WRS increase; worsened = ≥10% WRS decrease; if WRS remained 100%, ≥10 dB PTA change considered significant. On treatment: 40% improved, 53% stable, 7% worsened in target ears (6/15, 8/15, 1/15); reported as hearing preservation 93%. Median WRS 74% to 82%; median PTA 57 dB to 61 dB. After discontinuation (n=11), 82% stable and 18% hearing loss 94% had ≥1 adverse event; 50 total AEs: grade 1 62%, grade 2 34%, grade 3 4%, no grade 4/5. Hypertension 82% (grade 3 in 12%; 36% of hypertensive patients required antihypertensives), fatigue 29%, proteinuria 6%. Treatment discontinuation due to AEs in 29% Indications: progressive hearing loss 59%, other NF2 symptoms 35%, tumor size 6%. Symptoms improved in 41%, stable in 47%, worsened in 12% during treatment; summarized as clinical symptom improvement/preservation in 88%. Reasons for stopping included radiologic stability/regression and/or hearing benefit, AEs (29%), response failure (6%), patient preference (6%). After stopping (median surveillance 29.2 months), 27% remained stable and 73% worsened symptomatically; no further symptom improvement. Four patients were retreated with mixed results; two maintenance-regimen patients remained stable (douwes2024bevacizumabtreatmentfor pages 5-8, douwes2024bevacizumabtreatmentfor pages 9-11, douwes2024bevacizumabtreatmentfor pages 4-5, douwes2024bevacizumabtreatmentfor pages 8-9, douwes2024bevacizumabtreatmentfor pages 2-4)

Table: This table compiles the main quantitative bevacizumab outcomes for NF2-related vestibular schwannoma from a 2023 systematic review, a 2024 systematic review, and a 2024 single-center cohort. It is useful for comparing pooled efficacy, toxicity, and post-discontinuation patterns across evidence sources.

Real-world implementation example (single-center, 2013–2023): * Douwes et al. (Cancers, Apr 2024) used 7.5 mg/kg IV every 3 weeks (median duration 7.1 months) and reported hearing preservation 93%, with 31% tumor regression and 69% stable disease; adverse events were common (hypertension 82%; discontinuation due to AEs 29%) (douwes2024bevacizumabtreatmentfor pages 9-11, douwes2024bevacizumabtreatmentfor pages 4-5).

12.3 Emerging targeted and immunologic strategies (2023–2024)

  • Hippo pathway targeting (TEAD palmitoylation inhibitors): preclinical evidence supports regression of NF2-null schwannoma using TEAD inhibitors (Laraba et al., Brain 2023) (laraba2023inhibitionofyaptazdriven pages 1-2, laraba2023inhibitionofyaptazdriven media d8f8c3e0).
  • Combination immunotherapy + anti-VEGF (preclinical): combined anti-PD1 + anti-VEGF improved tumor control and preserved hearing in immune-competent VS models, suggesting a rationale for combination approaches (bioRxiv Dec 2024) (lu2024enhancedtumorcontrol pages 1-4).

12.4 Clinical trials and trial infrastructure

  • INTUITT-NF2 (NCT04374305): a randomized, open-label, phase II platform-basket master study testing multiple sub-studies (e.g., brigatinib; neratinib; retifanlimab + bevacizumab) with radiographic response rate by tumor type used for interim activity decisions; long-term observation up to 10 years (ClinicalTrials.gov; posted 2020; recruiting per retrieved metadata) (NCT04374305 chunk 1, NCT04374305 chunk 3).
  • Everolimus pre-surgical PK/PD (NCT01880749): early-phase study giving everolimus 10 mg daily for 10 days preoperatively and assessing phospho-S6 inhibition in tumor tissue (ClinicalTrials.gov; 2013) (NCT01880749 chunk 1).
  • Lapatinib concentration/activity (NCT00863122): endpoints include phospho-ErbB2 in tumor tissue at surgery and tumor markers after lapatinib exposure; includes NF2 mutation analysis and tissue drug concentration comparisons (ClinicalTrials.gov; 2009) (NCT00863122 chunk 2).

12.5 MAXO term suggestions (treatment actions)

  • Surgical excision of schwannoma: MAXO:0000004 Surgical procedure (general)
  • Stereotactic radiosurgery: MAXO:0000008 Radiotherapy (general)
  • Anti-VEGF therapy (bevacizumab): MAXO:0000753 Monoclonal antibody therapy (general)
  • Molecular targeted therapy trials (e.g., TEAD inhibitors, kinase inhibitors): MAXO:0000058 Targeted therapy (general)

13. Prevention

13.1 Primary prevention

No primary prevention strategies for sporadic schwannoma were identified in the retrieved evidence set.

13.2 Secondary prevention / surveillance

Perrino et al. (Clinical Cancer Research, Feb 2025) is explicitly focused on surveillance recommendations in pediatric NF2-, SMARCB1-, and LZTR1-related schwannomatosis, reflecting the shift toward structured screening/surveillance in gene-defined predisposition syndromes (perrino2025updateoncancer pages 3-4).

14. Other Species / Natural Disease

Not addressed in the retrieved evidence set.

15. Model Organisms

  • Mouse models and primary human tumor cell systems were used to establish the preclinical efficacy of TEAD palmitoylation inhibitors and genetic YAP/TAZ ablation in NF2-null schwannoma (laraba2023inhibitionofyaptazdriven pages 1-2).
  • Immune-competent syngeneic VS models were used to test anti-PD1 + anti-VEGF combination strategies with hearing preservation endpoints (lu2024enhancedtumorcontrol pages 1-4).

Expert synthesis and analysis (2023–2025 emphasis)

  1. Nosology and genetics have converged: a key recent development is the 2022 international consensus repositioning schwannomatosis as an umbrella term and renaming “neurofibromatosis type 2” to NF2-related schwannomatosis, with diagnosis increasingly driven by molecular evidence and explicit handling of mosaicism (tamura2024historicaldevelopmentof pages 1-3, tamura2024historicaldevelopmentof pages 3-4, perrino2025updateoncancer pages 3-4).
  2. Bevacizumab remains the most evidence-supported systemic therapy for NF2-related progressive VS, with consistent hearing preservation/tumor control signals across systematic reviews and real-world cohorts—tempered by hypertension and discontinuation rates and common post-discontinuation progression/relapse (chiranth2023asystematicreview pages 1-2, screnci2024bevacizumabforvestibular pages 1-2, douwes2024bevacizumabtreatmentfor pages 9-11).
  3. Mechanism-driven therapeutic opportunities are expanding: the Hippo–YAP/TAZ–TEAD axis has moved from correlative pathway dysregulation to direct, regressive preclinical intervention (TEAD palmitoylation inhibitors) in 2023 (laraba2023inhibitionofyaptazdriven pages 1-2, laraba2023inhibitionofyaptazdriven media d8f8c3e0). Platform trials such as INTUITT-NF2 represent a pragmatic clinical strategy to screen multiple targeted agents efficiently in rare NF2-related tumors (NCT04374305 chunk 1).

Key limitations of this report (due to retrieval constraints)

  • ICD-10/ICD-11, MeSH, Orphanet, OMIM IDs for schwannoma/VS were not retrieved in the current tool context.
  • Environmental/lifestyle risk factors, protective factors, and gene–environment interactions were not supported by evidence in the retrieved excerpts.
  • Broad epidemiology for all schwannomas (beyond NF2-related statistics) and detailed histopathology/IHC differentials were not extractable from the current corpus.

References

  1. (otaner2026vestibularschwannomagenetic pages 1-2): Franciska Otaner, Vratko Himic, Luis O. Vargas, Matthew Abikenari, Neelesh Pandey, Shayndhan Sivanathan, Olivia Kalmanson, Aparna Govindan, Diane Jung, Dagoberto Estevez-Ordonez, Amy Wang, Sanjeeva Jeyaretna, Ashish H. Shah, Ricardo J. Komotar, Bradley Gampel, Christine Dinh, and Michael E. Ivan. Vestibular schwannoma: genetic and epigenetic mechanisms, hearing loss, and emerging therapies. Journal of Neuro-Oncology, May 2026. URL: https://doi.org/10.1007/s11060-026-05621-4, doi:10.1007/s11060-026-05621-4. This article has 0 citations and is from a peer-reviewed journal.

  2. (screnci2024bevacizumabforvestibular pages 1-2): Melina Screnci, Mathilde Puechmaille, Quentin Berton, Toufic Khalil, Thierry Mom, and Guillaume Coll. Bevacizumab for vestibular schwannomas in neurofibromatosis type 2: a systematic review of tumor control and hearing preservation. Journal of Clinical Medicine, 13:7488, Dec 2024. URL: https://doi.org/10.3390/jcm13237488, doi:10.3390/jcm13237488. This article has 7 citations.

  3. (OpenTargets Search: schwannoma,vestibular schwannoma,schwannomatosis): Open Targets Query (schwannoma,vestibular schwannoma,schwannomatosis, 7 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  4. (perrino2025updateoncancer pages 3-4): Melissa R. Perrino, Marjolijn C. J. Jongmans, Gail E. Tomlinson, Mary-Louise C. Greer, Sarah R. Scollon, Sarah G. Mitchell, Jordan R. Hansford, Kris Ann P. Schultz, Wendy K. Kohlmann, Jennifer M. Kalish, Suzanne P. MacFarland, Anirban Das, Kara N. Maxwell, Stefan M. Pfister, Rosanna Weksberg, Orli Michaeli, Uri Tabori, Gina M. Ney, Philip J. Lupo, Jack J. Brzezinski, Douglas R. Stewart, Emma R. Woodward, and Christian P. Kratz. Update on cancer and central nervous system tumor surveillance in pediatric nf2-, smarcb1-, and lztr1-related schwannomatosis. Clinical cancer research : an official journal of the American Association for Cancer Research, Feb 2025. URL: https://doi.org/10.1158/1078-0432.ccr-24-3278, doi:10.1158/1078-0432.ccr-24-3278. This article has 8 citations.

  5. (rai2025classificationofschwannomas pages 1-2): Pranjal Rai, Girish Bathla, Neetu Soni, Amit Desai, Dinesh Rao, Prasanna Vibhute, and Amit Agarwal. Classification of schwannomas and the new naming convention for "neurofibromatosis-2": genetic updates and international consensus recommendation. The neuroradiology journal, pages 19714009251313510, Jan 2025. URL: https://doi.org/10.1177/19714009251313510, doi:10.1177/19714009251313510. This article has 7 citations and is from a peer-reviewed journal.

  6. (tamura2024historicaldevelopmentof pages 1-3): Ryota TAMURA, Masahiro YO, and Masahiro TODA. Historical development of diagnostic criteria for nf2-related schwannomatosis. Neurologia medico-chirurgica, 64:299-308, Aug 2024. URL: https://doi.org/10.2176/jns-nmc.2024-0067, doi:10.2176/jns-nmc.2024-0067. This article has 12 citations and is from a peer-reviewed journal.

  7. (chiranth2023asystematicreview pages 1-2): Shivani Chiranth, Seppo W Langer, Hans Skovgaard Poulsen, and Thomas Urup. A systematic review of targeted therapy for vestibular schwannoma in patients with nf2-related schwannomatosis. Neuro-Oncology Advances, Aug 2023. URL: https://doi.org/10.1093/noajnl/vdad099, doi:10.1093/noajnl/vdad099. This article has 27 citations and is from a peer-reviewed journal.

  8. (douwes2024bevacizumabtreatmentfor pages 9-11): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 15 citations.

  9. (NCT04374305 chunk 1): Scott R. Plotkin, MD, PhD. Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2). Scott R. Plotkin, MD, PhD. 2020. ClinicalTrials.gov Identifier: NCT04374305

  10. (tamura2024historicaldevelopmentof pages 3-4): Ryota TAMURA, Masahiro YO, and Masahiro TODA. Historical development of diagnostic criteria for nf2-related schwannomatosis. Neurologia medico-chirurgica, 64:299-308, Aug 2024. URL: https://doi.org/10.2176/jns-nmc.2024-0067, doi:10.2176/jns-nmc.2024-0067. This article has 12 citations and is from a peer-reviewed journal.

  11. (lu2024enhancedtumorcontrol pages 1-4): Simeng Lu, Zhenzhen Yin, Limeng Wu, Yao Sun, Jie Chen, Lai Man Natalie Wu, Janet L. Oblinger, Day Caven Blake, Lukas D. Landegger, Richard Seist, William Ho, Bingyu Xiu, Adam P. Jones, Alona Muzikansky, Konstantina M. Stankovic, Scott R. Plotkin, Long-Sheng Chang, and Lei Xu. Enhanced tumor control and hearing loss prevention achieved with combined immune checkpoint inhibitor and anti-vegf therapy in vestibular schwannoma model. bioRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.29.630658, doi:10.1101/2024.12.29.630658. This article has 3 citations.

  12. (perrino2025updateoncancer pages 5-7): Melissa R. Perrino, Marjolijn C. J. Jongmans, Gail E. Tomlinson, Mary-Louise C. Greer, Sarah R. Scollon, Sarah G. Mitchell, Jordan R. Hansford, Kris Ann P. Schultz, Wendy K. Kohlmann, Jennifer M. Kalish, Suzanne P. MacFarland, Anirban Das, Kara N. Maxwell, Stefan M. Pfister, Rosanna Weksberg, Orli Michaeli, Uri Tabori, Gina M. Ney, Philip J. Lupo, Jack J. Brzezinski, Douglas R. Stewart, Emma R. Woodward, and Christian P. Kratz. Update on cancer and central nervous system tumor surveillance in pediatric nf2-, smarcb1-, and lztr1-related schwannomatosis. Clinical cancer research : an official journal of the American Association for Cancer Research, Feb 2025. URL: https://doi.org/10.1158/1078-0432.ccr-24-3278, doi:10.1158/1078-0432.ccr-24-3278. This article has 8 citations.

  13. (xu2024nf2anunderestimated pages 2-3): Duo Xu, Shiyuan Yin, and Yongqian Shu. Nf2: an underestimated player in cancer metabolic reprogramming and tumor immunity. NPJ Precision Oncology, Jun 2024. URL: https://doi.org/10.1038/s41698-024-00627-5, doi:10.1038/s41698-024-00627-5. This article has 34 citations and is from a peer-reviewed journal.

  14. (laraba2023inhibitionofyaptazdriven pages 1-2): Liyam Laraba, Lily Hillson, Julio Grimm de Guibert, Amy Hewitt, Maisie R Jaques, Tracy T Tang, Leonard Post, Emanuela Ercolano, Ganesha Rai, Shyh-Ming Yang, Daniel J Jagger, Waldemar Woznica, Philip Edwards, Aditya G Shivane, C Oliver Hanemann, and David B Parkinson. Inhibition of yap/taz-driven tead activity prevents growth of nf2-null schwannoma and meningioma. Brain, 146:1697-1713, Sep 2023. URL: https://doi.org/10.1093/brain/awac342, doi:10.1093/brain/awac342. This article has 64 citations and is from a highest quality peer-reviewed journal.

  15. (laraba2023inhibitionofyaptazdriven pages 2-3): Liyam Laraba, Lily Hillson, Julio Grimm de Guibert, Amy Hewitt, Maisie R Jaques, Tracy T Tang, Leonard Post, Emanuela Ercolano, Ganesha Rai, Shyh-Ming Yang, Daniel J Jagger, Waldemar Woznica, Philip Edwards, Aditya G Shivane, C Oliver Hanemann, and David B Parkinson. Inhibition of yap/taz-driven tead activity prevents growth of nf2-null schwannoma and meningioma. Brain, 146:1697-1713, Sep 2023. URL: https://doi.org/10.1093/brain/awac342, doi:10.1093/brain/awac342. This article has 64 citations and is from a highest quality peer-reviewed journal.

  16. (laraba2023inhibitionofyaptazdriven media d8f8c3e0): Liyam Laraba, Lily Hillson, Julio Grimm de Guibert, Amy Hewitt, Maisie R Jaques, Tracy T Tang, Leonard Post, Emanuela Ercolano, Ganesha Rai, Shyh-Ming Yang, Daniel J Jagger, Waldemar Woznica, Philip Edwards, Aditya G Shivane, C Oliver Hanemann, and David B Parkinson. Inhibition of yap/taz-driven tead activity prevents growth of nf2-null schwannoma and meningioma. Brain, 146:1697-1713, Sep 2023. URL: https://doi.org/10.1093/brain/awac342, doi:10.1093/brain/awac342. This article has 64 citations and is from a highest quality peer-reviewed journal.

  17. (douwes2024bevacizumabtreatmentfor pages 2-4): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 15 citations.

  18. (douwes2024bevacizumabtreatmentfor pages 8-9): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 15 citations.

  19. (douwes2024bevacizumabtreatmentfor pages 5-8): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 15 citations.

  20. (douwes2024bevacizumabtreatmentfor pages 4-5): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 15 citations.

  21. (NCT04374305 chunk 3): Scott R. Plotkin, MD, PhD. Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2). Scott R. Plotkin, MD, PhD. 2020. ClinicalTrials.gov Identifier: NCT04374305

  22. (NCT01880749 chunk 1): Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas. NYU Langone Health. 2013. ClinicalTrials.gov Identifier: NCT01880749

  23. (NCT00863122 chunk 2): Concentration and Activity of Lapatinib in Vestibular Schwannomas. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. 2009. ClinicalTrials.gov Identifier: NCT00863122

Artifacts